Opportunities for future biological therapy in SLE

D. Wofsy, D. I. Daikh

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.

Original languageEnglish (US)
Pages (from-to)529-541
Number of pages13
JournalBailliere's Clinical Rheumatology
Volume12
Issue number3
DOIs
StatePublished - 1998
Externally publishedYes

Keywords

  • Interleukin 10
  • Interleukin 6
  • Murine lupus
  • T cell co-stimulation
  • Tumour necrosis factor-α

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Opportunities for future biological therapy in SLE'. Together they form a unique fingerprint.

Cite this